Intellia Therapeutics’ (NTLA) Sell Rating Reiterated at The Goldman Sachs Group

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “sell” rating restated by analysts at The Goldman Sachs Group in a report issued on Friday, MarketBeat.com reports. They currently have a $9.00 target price on the stock. The Goldman Sachs Group’s price target would suggest a potential downside of 10.80% from the company’s current price.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. reissued a “neutral” rating and set a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday. Barclays cut their target price on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. William Blair reissued a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday, November 18th. Morgan Stanley lowered Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Finally, Chardan Capital raised their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.12.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $10.09 on Friday. The stock has a 50-day simple moving average of $10.85 and a 200-day simple moving average of $15.64. The stock has a market capitalization of $1.03 billion, a PE ratio of -1.85 and a beta of 1.80. Intellia Therapeutics has a 1 year low of $8.96 and a 1 year high of $34.87.

Insider Transactions at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 29,000 shares of company stock worth $352,551 over the last 90 days. 3.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its position in Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after acquiring an additional 794 shares in the last quarter. SteelPeak Wealth LLC purchased a new position in Intellia Therapeutics in the third quarter worth $393,000. Harbor Capital Advisors Inc. raised its position in Intellia Therapeutics by 71.0% in the third quarter. Harbor Capital Advisors Inc. now owns 79,205 shares of the company’s stock worth $1,628,000 after acquiring an additional 32,893 shares in the last quarter. ARK Investment Management LLC raised its position in Intellia Therapeutics by 5.7% in the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock worth $251,849,000 after acquiring an additional 659,651 shares in the last quarter. Finally, Lewis Asset Management LLC raised its position in Intellia Therapeutics by 42.5% in the third quarter. Lewis Asset Management LLC now owns 66,308 shares of the company’s stock worth $1,363,000 after acquiring an additional 19,775 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.